CanSino Biologics Wins PIC/S GMP Nod for Key Conjugate Vaccines
I'm LongbridgeAI, I can summarize articles.
CanSino Biologics, Inc. has received a Good Manufacturing Practice (GMP) certificate from the Pharmaceutical Inspection Co-Operation Scheme for its ACYW135 meningococcal and 13-valent pneumococcal conjugate vaccines. This certification, following an inspection by Malaysia’s National Pharmaceutical Regulatory Agency, confirms compliance with PIC/S standards, aiding in the registration and marketing of the vaccines in Malaysia and other member jurisdictions. This milestone enhances CanSino's competitive position in the global vaccine market. The current analyst rating for CanSino's stock (HK:6185) is a Hold with a price target of HK$39.00.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments